HealthCap

Aro Biotherapeutics Announces Leadership Transition and Appoints Purnanand Sarma as Chief Executive Officer Most welcome Purnanand, we are looking forward working with you! www.healthcap.eu/ETzs

I'm excited to share that our CT-0508 Phase 1 trial results are published today in Nature Medicine. This first-in-human CAR-Macrophage trial for heavily pre-treated advanced/metastatic HER2 over-expressing solid tumors demonstrates that CAR-M therapy is feasible and well-tolerated. The translational findings validate the CAR-M mechanism of action, showing anti-tumor activity, TME remodeling, and induction of anti-tumor T cell immunity. Notably, ctDNA analysis revealed that a single dose of CAR-M induced robust, but transient, anti-tumor activity in pts with HER2 3+ tumors.   Building on this progress we are advancing CT-1119, an anti-mesothelin CAR-Monocyte with a next-gen CAR and SIRPa silencing, into a Phase 1 trial for ovarian and pancreatic cancers this year. This trial will include repeat dosing and combination with anti-PD1 to enhance and extend potential anti-tumor activity. CT-1119 data are expected in 4Q 2025. Thank you to the patients and their families that participated in the trial, the phenomenal oncologists and their teams, the Carisma Therapeutics team, and Thomas Condamine for his leadership.   Full publication below: https://lnkd.in/endpEv_J

Fantastic and important news from our portfolio company Ariceum! U.S. FDA Grants Orphan Drug Designation to Ariceum Therapeutics’ Proprietary Radiopharmaceutical Cancer Therapy www.healthcap.eu/skqE

Exciting news from Aro! Aro Biotherapeutics Announces U.S. FDA Clearance of IND Application for ABX1100 for Potential Treatment of Late-Onset Pompe Disease (LOPD) www.healthcap.eu/RKBf

Excellent news! 🚀 We congratulate the Vicore team on this important milestone. The FDA Grants Vicore’s Buloxibutid Fast Track Designation for Idiopathic Pulmonary Fibrosis www.healthcap.eu/mIFC

Oncopeptides’ Pepaxti formally approved for full reimbursement in Italy www.healthcap.eu/xTuI

Exciting News! 🚀Aro Biotherapeutics Doses First Patient in Phase 1b Trial of ABX1100 in Late-Onset Pompe Disease (LOPD) www.healthcap.eu/sUVy

For all orthopedic, trauma and podiatry surgeons on LInkedIn treating diabetic patients with osteomyelitis (bone infections): dramatic improvement in 5-year survival within the CERAMENT G/V(antibiotic eluting bone void filler) group: 87.5%, compared to 44.9% in the standard treatment group (no local antibiotic) [Mortality rate 12.5%, vs 55.1%, p<0.00001]. WOW Proud of the work of BONESUPPORT AB in bringing these products to the market. From the paper: NLAB no local antibx; LAC local antibx with CERAMENT G or CERAMENT V: Infection healing was demonstrated in 10 (20.41%) patients from group NLAB and 41 (73.21%) from group LAB (p < 0.0001). Persistence of infection with no evidence of wound healing, 6 months from surgery, was observed in 15 (30.61%) patients in group NLAB. Among the LAB group, only 4 (7.14%) patients demonstrated infection persistence (p = 0.00183). Reinfection was observed in 24 of 49 patients in group NLAB (49%) and in only 11 out of 56 patients in group LAB (20%) (p = 0.001466). 7 (6.67%) patients required major amputation with 6 (12.24%) belonging to group NLAB. Only 1 (1.78%) patient in group LAB underwent major amputation. A higher 5-year mortality rate was noted within patients in group NLAB, 27 (55.1%). The mortality rate in group LAB was (12.5%). This was a retrospective study, so has limitations of course. For disclosure I am on the board of BoneSupport which manufactures CERAMENT.

Exciting and important news - FDA Clears Ariceum Therapeutics’ 225Ac-Satoreotide Phase I/II Clinical Study in Patients with Small Cell Lung Cancer or Merkel Cell Carcinoma www.healthcap.eu/GHif

Ariceum Therapeutics and ITM Enter Supply Agreement for Therapeutic Medical Radioisotope Actinium-225 www.healthcap.eu/eHuz